Definitions in hemophilia: Communication from the SSC of the ISTH

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 11, 2014, Pages 1935-1939

  Blanchette, V S ^a   Key, N S ^b   Ljung, L R ^c   Manco Johnson, M J ^d   van den Berg, H M ^e   Srivastava, A ^f  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COAGULATING AGENT;

BLOOD; CLASSIFICATION; DISEASE COURSE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; NOMENCLATURE; PRACTICE GUIDELINE; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

COAGULANTS; DISEASE PROGRESSION; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 84920286350     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12672     Document Type: Article

References (19)

1. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, on behalf of the Factor VIII and Factor IX Subcommittee. Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
2. Aledort LM, Haschmeyer RH, Pettersson H, the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236: 391-9.
3. Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M, Mancuso ME, Mazzucconi MG, Pasta GL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP, Mannucci PM, on behalf of the Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114: 779-84.
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
5. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
6. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I, the Association of Hemophilia Centre Directors of Canada. On behalf of the Factor VIII/IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-5.
7. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assurance program of the ECAT Foundation. Sem Thromb Haemost 2009; 35: 786-93.
8. Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Hay CR. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013; 160: 153-70.
9. Bjorkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of Factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin Pharmacokinet 1992; 22: 385-95.
10. Dardikh M, Albert T, Masereeuw R, Oldenburg J, Novakova I, van Heerde WL, Verbruggen B. Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction. J Thromb Haemost 2012; 10: 706-8.
11. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM, the Hemophilia Inhibitor Research Study Investigators. Validation of the Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost 2012; 10: 1055-61.
12. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PLF, Gringeri A, Ljung RC, Manco-Johnson MJ, Morfini M, Kilcoyne RF, Petrini P, Rodriguez Merchan EC, Schramm W, Shapiro A, van den Berg HM, Hart C. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
13. Donadel-Claeyssens S, on behalf of the European Paediatric Network for Haemophilia Management. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia 2006; 12: 124-7.
14. Ota S, McLimont M, Carcao MD, Blanchette VS, Graham N, Paradis E, Feldman BM. Definitions for haemophilia prophylaxis and its outcomes: the Canadian Consensus Study. Haemophilia 2007; 13: 12-20.
15. Gringeri A, Lambert T, Street A, Aledort L. Tertiary prophylaxis in adults: is there a rationale? Haemophilia 2012; 18: 727-8.
16. Fischer K, van den Bom JG, Mauser-Bunschoten EP, Rosendaal G, Prejs R, de Kleijn P, Grobbee DE, van den Berg M. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002; 99: 2337-41.
17. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci M, the Esprit Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
18. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
19. Blanchette VS, McCready M, Achonu C, Abdolell M, Rivard G, Manco-Johnson MJ. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003; 9 (Suppl. 1): 19-26.